We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
-13.19%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.78B
AUM Growth
+$18.3M
Cap. Flow
+$443M
Cap. Flow %
15.93%
Top 10 Hldgs %
42.27%
Holding
179
New
61
Increased
32
Reduced
13
Closed
19

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$37.6M
2
UNH icon
UnitedHealth
UNH
+$37.4M
3
UTHR icon
United Therapeutics
UTHR
+$29.3M
4
MRK icon
Merck
MRK
+$27.6M
5
A icon
Agilent Technologies
A
+$24.1M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$27.7M
2
CELG
Celgene Corp
CELG
+$26.8M
3
CTRX
CATAMARAN CORP COM STK (CDA)
CTRX
+$26.5M
4
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$23.7M
5
ACOR
Acorda Therapeutics
ACOR
+$22.7M

Sector Composition

Rank Sector Weight
1 Healthcare 81.09%
2 Real Estate 3.47%
3 Financials 1.31%
4 Technology 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AEGR
126
DELISTED
Aegerion Pharmaceuticals
AEGR
$2.8M 0.1%
206,000
– –
DCOY
127
Decoy Therapeutics
DCOY
$2.09M
– –
0
– –
CCP
128
DELISTED
Care Capital Properties, Inc.
CCP
$2.78M 0.1%
+84,316
New +$2.73M
MPT
129
CALL
Medical Properties Trust
MPT
$2.81B
$2.67M 0.1%
+70,300
New +$872K
GRFS
130
Grifois
GRFS
$5.58B
$2.52M 0.09%
+166,000
New +$2.63M
MNTA
131
DELISTED
Momenta Pharmaceuticals, Inc.
MNTA
$2.52M 0.09%
+153,700
New +$3.15M
ESPR
132
CALL
DELISTED
Esperion Therapeutics
ESPR
$2.42M 0.09%
102,800
-45,200
-31% -$2.84M
ESPR
133
DELISTED
Esperion Therapeutics
ESPR
$2.42M 0.09%
102,800
-45,200
-31% -$2.84M
ALNY icon
134
CALL
Alnylam Pharmaceuticals
ALNY
$27.4B
$2.37M 0.09%
+29,500
New +$3.28M
AXDX
135
DELISTED
Accelerate Diagnostics
AXDX
$2.34M 0.08%
14,463
– –
DBVT
136
DBV Technologies
DBVT
$817M
$2.33M 0.08%
+6,560
New +$2.58M
QURE icon
137
CALL
uniQure
QURE
$2.93B
$2.1M 0.08%
+102,800
New +$2.71M
QURE icon
138
uniQure
QURE
$2.93B
$2.1M 0.08%
+102,800
New +$2.71M
CMRX
139
DELISTED
Chimerix, Inc.
CMRX
$1.83M 0.07%
+47,800
New +$2.36M
GNMK
140
DELISTED
GenMark Diagnostics, Inc
GNMK
$1.69M 0.06%
215,149
– –
TTPH
141
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
– –
0
– –
AFMD
142
DELISTED
Affimed
AFMD
$1.41M 0.05%
+22,808
New +$2.83M
BDSI
143
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$1.39M 0.05%
250,000
– –
ABAX
144
DELISTED
Abaxis Inc
ABAX
$988K 0.04%
22,466
– –
VSTM icon
145
Verastem
VSTM
$536M
$895K 0.03%
41,667
-62,485
-60% -$4.95M
BLCM
146
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$872K 0.03%
6,000
– –
TRIL
147
DELISTED
Trillium Therapeutics Inc.
TRIL
$847K 0.03%
65,000
– –
LKFT
148
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.81B
$814K 0.03%
20,000
– –
CYNA
149
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
$799K 0.03%
+49,322
New +$801K
CDTX
150
DELISTED
Cidara Therapeutics
CDTX
$636K 0.02%
2,500
– –
3 4 5
6
7

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q3 2015 Portfolio in Review

As of Q3 2015, Tekla Capital Management held 179 positions worth $2.78B, up 0.66% from $2.76B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Tekla Capital Management deployed $443M of net new capital in Q3 2015, opening 61 new positions and adding to 32 existing holdings. Its largest new stake was UnitedHealth: 312,600 shares worth $36.3M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 84% a quarter earlier, followed by Real Estate and Financials.

On the sell side, the largest reduction was Amgen, an estimated $27.7M trimmed.

  • Tekla Capital Management's largest Q3 2015 buy was UnitedHealth: 312,600 shares worth $36.3M.
  • Tekla Capital Management added most to Biogen in Q3 2015, an estimated $37.6M increase.
  • Tekla Capital Management's biggest Q3 2015 reduction was Amgen, cutting an estimated $27.7M.
  • Tekla Capital Management fully exited CATAMARAN CORP COM STK (CDA) in Q3 2015, selling an estimated $26.5M.
  • Tekla Capital Management's ten largest holdings make up 42% of its $2.78B portfolio in Q3 2015.
  • Tekla Capital Management opened 61 new positions and closed 19 in Q3 2015.
  • Tekla Capital Management's portfolio value rose 0.66% quarter-over-quarter to $2.78B.

Based on Tekla Capital Management's 13F filing for Q3 2015, filed 13 Nov 2015.